Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 11,344 matching trials from the live ClinicalTrials.gov search.
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Depodur vs Fentanyl Infusion for Post-C/S Analgesia

NCT00762554
Conditions
Analgesia
Interventions
Depodur, Fentanyl
Drug
Lead sponsor
Goodman, Evan, M.D.
Individual
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Neoplasms, Hematologic
Interventions
120 mg LY2784544
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Burbank, California • Norwalk, Connecticut + 19 more
Conditions
Hypertrophic Cardiomyopathy
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
DNA ploidy analysis, comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • Downey, California • Loma Linda, California + 48 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab, Simtuzumab placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
45 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Conditions
Restless Legs Syndrome (RLS), Restless Legs Syndrome
Interventions
ropinirole CR-RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Jasper, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 41 more
Conditions
Acute Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Sarasota, Florida + 13 more
Conditions
Malignant Glioma
Interventions
Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
111
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
riliprubart, Placebo, IVIg
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
32
States / cities
Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more
Conditions
Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture, Closed Lower Extremity Fracture, Pelvic Fracture
Interventions
DuraPrep, ChloraPrep
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
8,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
24
States / cities
Irvine, California • Los Angeles, California • San Jose, California + 20 more
Conditions
ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell Cancer, Recurrent, Clear Cell Renal Cell Cancer (ccRCC)
Interventions
177Lu-TLX250
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
8
States / cities
Duarte, California • San Diego, California • Miami, Florida + 5 more
Conditions
Head and Neck Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Detroit, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

NCT05954286
Conditions
SARS-CoV-2
Interventions
Upamostat, Placebo (PO)
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee
Conditions
Breast Cancer
Interventions
2-dimensional mammogram, digital breast tomosynthesis (DBT)
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
25 Years to 85 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Assessment of Therapy Complications, Carboplatin, Filgrastim, Paclitaxel, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
75 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
357
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 245 more
Conditions
Lower Extremity Acute Limb Ischemia, LE ALI
Interventions
Indigo Aspiration System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Stanford, California • Danbury, Connecticut • Bradenton, Florida + 11 more
Active, not recruiting Not applicable Interventional

Project 3: ACHIEVE- CHD

NCT05918380
Conditions
Coronary Heart Disease
Interventions
PAL2, CINEMA
Behavioral · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
ABT-751, Placebo, Docetaxel
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Burbank, California • Orange, California + 10 more
Conditions
Augmented Renal Clearance (ARC), Systemic Inflammatory Response Syndrome (SIRS)
Interventions
Ceftaroline fosamil/Avibactam (CXL)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
19
States / cities
Fresno, California • Los Angeles, California • San Diego, California + 16 more
Conditions
Varicella
Interventions
VARIVAX® PE34 Process, VARIVAX® 2016 Commercial Process, M-M-R II®
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Months to 23 Months
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Anaheim, California + 32 more
Conditions
Multiple Sclerosis
Interventions
MRI Contrast
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Cleveland, Ohio • Philadelphia, Pennsylvania
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Conditions
Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Thiotepa, Total Body Irradiation, Double Umbilical Cord Transplant, Tacrolimus, Mycophenolate Mofetil, Abatacept
Drug · Radiation · Biological
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio